Ascendis FDA OK for Once-Weekly Treatment for Growth Hormone Deficiency

 

• First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease company
• On track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, and SGA*, as well as combination therapy trials in achondroplasia and hypochondroplasia, in Q4 2025

https://finviz.com/news/116962/fda-approves-skytrofa-lonapegsomatropin-tcgd-for-the-once-weekly-treatment-of-adults-with-growth-hormone-deficiency